Compare · BHC vs NVO
BHC vs NVO
Side-by-side comparison of Bausch Health Companies Inc. (BHC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 95.6x BHC ($2.01B).
- Over the past year, BHC is up 6.4% and NVO is down 45.2% - BHC leads by 51.6 points.
- BHC has been more active in the news (15 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for BHC).
- Company
- Bausch Health Companies Inc.
- Novo Nordisk A/S
- Price
- $5.17-4.00%
- $41.34-3.71%
- Market cap
- $2.01B
- $191.82B
- 1M return
- -9.70%
- -9.75%
- 1Y return
- +6.39%
- -45.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 15
- 8
- Recent ratings
- 10
- 25
Bausch Health Companies Inc.
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BHC
- SEC Form SD filed by Bausch Health Companies Inc.
- Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
- Director Wechsler Amy B was granted 45,871 shares, increasing direct ownership by 17% to 313,585 units (SEC Form 4)
- Director Roberts Eiry was granted 45,871 shares (SEC Form 4)
- Director Power Robert N was granted 45,871 shares, increasing direct ownership by 18% to 300,594 units (SEC Form 4)
- Director Paulson John was granted 45,871 shares, increasing direct ownership by 12% to 417,565 units (SEC Form 4)
- Director Leung Sandra was granted 45,871 shares, increasing direct ownership by 103% to 90,225 units (SEC Form 4)
- Director Lee Frank D. was granted 45,871 shares, increasing direct ownership by 93% to 95,210 units (SEC Form 4)
- Director Kavanagh Sarah B was granted 45,871 shares, increasing direct ownership by 19% to 282,230 units (SEC Form 4)
- Director Goettler Michael was granted 45,871 shares, increasing direct ownership by 152% to 76,020 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care